論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).
掲載誌名	正式名：International journal of hematology 略　 称：Int J Hematol ISSNコード：18653774/09255710
掲載区分	国外
巻・号・頁	123(3),pp.404-411
著者・共著者	Atsushi Satake, Yasuhiro Nagate, Kohta Miyawaki, Yuki Fujiwara, Shuichi Ota, Tsuyoshi Muta, Shinya Rai, Hisashi Tsurumi, Ritsuro Suzuki, Takaaki Miyake, Hideki Goto, Noriko Fukuhara, Mamiko Sakata-Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Takahiro Kumode, Daisuke Ennishi, Takayuki Shimose, Naoki Inubashiri, Itaru Matsumura, Koichi Akashi, Koji Kato
発行年月	2026/03
概要	Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) was approved in Japan for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in 2022, based on findings of the POLARIX study (NCT03274492). Reports on real-world usage of Pola-R-CHP are lacking. Here we report safety and response rates at end of treatment (EOT) for Pola-R-CHP in Japan from the real-world observational POLASTAR study (jRCT1071220082). Patients (≥ 18 years) with previously untreated DLBCL who were scheduled to receive Pola-R-CHP were enrolled. The primary endpoint was overall survival. As of December 20, 2023, the full analysis set (FAS) included 192 of the initial 199 patients enrolled. Median age was 71.0 years (range 30-91). In the FAS, 99 (51.6%) patients had Grade ≥ 3 adverse events (AEs), 29 (15.1%) had serious AEs, and 15 (7.8%) discontinued polatuzumab vedotin due to AEs. In the efficacy-evaluable population at EOT (n = 141), the overall response rate was 95.0% [95% confidence interval (CI), 90.1-97.6], and the complete response rate was 87.9% (95% CI, 81.5-92.3). These results are consistent with published data from POLARIX. The POLASTAR study is ongoing; the recruitment target of 500 patients has been reached.Clinical trial registration: Japan Registry of Clinical Trials (jRCT1071220082).
DOI	10.1007/s12185-025-04122-w
PMID	41335368